A population-based case-control teratologic study of oral chloramphenicol treatment during pregnancy

E. Czeizel, M. Rockenbauer, Henrik T. Sørensen, Jørn Olsen

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The objective of the study was to check the human teratogenic potential of oral chloramphenicol treatments during pregnancy. Pair analysis of cases with congenital abnormalities and matched population controls was performed in the large population-based dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1996. Of 38,151 pregnant women who had babies without any defects (control group), 51 (0.13%), while of 22,865 pregnant women who had newborn infants or fetuses with congenital abnormalities, 52 (0.23%) pregnant women were treated with oral chloramphenicol. The case-control pair analysis did not show any human teratogenic potential of chloramphenicol during the second-third months of pregnancy in the different groups of congenital abnormalities. The occurrence of chloramphenicol treatment in the total control group as referent was compared with the occurrence of chloramphenicol treatment in the different congenital abnormality groups during the second-third months of gestation (i.e., in the critical period for major congenital abnormalities) and a higher adjusted OR for this drug was found only in the group with undescended testis based on only two cases. At the evaluation of medically documented chloramphenicol treatment a higher OR was not found in any congenital abnormalities. Thus, chloramphenicol treatment during early pregnancy presents little, if any, teratogenic risk to the fetus in humans.

Original languageEnglish
Pages (from-to)323-327
Number of pages5
JournalEuropean Journal of Epidemiology
Volume16
Issue number4
DOIs
Publication statusPublished - 2000

Fingerprint

Chloramphenicol
Case-Control Studies
Pregnancy
Population
Pregnant Women
Therapeutics
Fetus
Control Groups
Cryptorchidism
Population Control
Newborn Infant
Pharmaceutical Preparations

Keywords

  • Case-control analysis
  • Chloramphenicol
  • Congenital abnormalities
  • Human teratogenic potential

ASJC Scopus subject areas

  • Epidemiology

Cite this

A population-based case-control teratologic study of oral chloramphenicol treatment during pregnancy. / Czeizel, E.; Rockenbauer, M.; Sørensen, Henrik T.; Olsen, Jørn.

In: European Journal of Epidemiology, Vol. 16, No. 4, 2000, p. 323-327.

Research output: Contribution to journalArticle

@article{a0d4ab3c0560475f8f4bdfd6a706fb3d,
title = "A population-based case-control teratologic study of oral chloramphenicol treatment during pregnancy",
abstract = "The objective of the study was to check the human teratogenic potential of oral chloramphenicol treatments during pregnancy. Pair analysis of cases with congenital abnormalities and matched population controls was performed in the large population-based dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1996. Of 38,151 pregnant women who had babies without any defects (control group), 51 (0.13{\%}), while of 22,865 pregnant women who had newborn infants or fetuses with congenital abnormalities, 52 (0.23{\%}) pregnant women were treated with oral chloramphenicol. The case-control pair analysis did not show any human teratogenic potential of chloramphenicol during the second-third months of pregnancy in the different groups of congenital abnormalities. The occurrence of chloramphenicol treatment in the total control group as referent was compared with the occurrence of chloramphenicol treatment in the different congenital abnormality groups during the second-third months of gestation (i.e., in the critical period for major congenital abnormalities) and a higher adjusted OR for this drug was found only in the group with undescended testis based on only two cases. At the evaluation of medically documented chloramphenicol treatment a higher OR was not found in any congenital abnormalities. Thus, chloramphenicol treatment during early pregnancy presents little, if any, teratogenic risk to the fetus in humans.",
keywords = "Case-control analysis, Chloramphenicol, Congenital abnormalities, Human teratogenic potential",
author = "E. Czeizel and M. Rockenbauer and S{\o}rensen, {Henrik T.} and J{\o}rn Olsen",
year = "2000",
doi = "10.1023/A:1007623408010",
language = "English",
volume = "16",
pages = "323--327",
journal = "European Journal of Epidemiology",
issn = "0393-2990",
publisher = "Springer Netherlands",
number = "4",

}

TY - JOUR

T1 - A population-based case-control teratologic study of oral chloramphenicol treatment during pregnancy

AU - Czeizel, E.

AU - Rockenbauer, M.

AU - Sørensen, Henrik T.

AU - Olsen, Jørn

PY - 2000

Y1 - 2000

N2 - The objective of the study was to check the human teratogenic potential of oral chloramphenicol treatments during pregnancy. Pair analysis of cases with congenital abnormalities and matched population controls was performed in the large population-based dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1996. Of 38,151 pregnant women who had babies without any defects (control group), 51 (0.13%), while of 22,865 pregnant women who had newborn infants or fetuses with congenital abnormalities, 52 (0.23%) pregnant women were treated with oral chloramphenicol. The case-control pair analysis did not show any human teratogenic potential of chloramphenicol during the second-third months of pregnancy in the different groups of congenital abnormalities. The occurrence of chloramphenicol treatment in the total control group as referent was compared with the occurrence of chloramphenicol treatment in the different congenital abnormality groups during the second-third months of gestation (i.e., in the critical period for major congenital abnormalities) and a higher adjusted OR for this drug was found only in the group with undescended testis based on only two cases. At the evaluation of medically documented chloramphenicol treatment a higher OR was not found in any congenital abnormalities. Thus, chloramphenicol treatment during early pregnancy presents little, if any, teratogenic risk to the fetus in humans.

AB - The objective of the study was to check the human teratogenic potential of oral chloramphenicol treatments during pregnancy. Pair analysis of cases with congenital abnormalities and matched population controls was performed in the large population-based dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities, 1980-1996. Of 38,151 pregnant women who had babies without any defects (control group), 51 (0.13%), while of 22,865 pregnant women who had newborn infants or fetuses with congenital abnormalities, 52 (0.23%) pregnant women were treated with oral chloramphenicol. The case-control pair analysis did not show any human teratogenic potential of chloramphenicol during the second-third months of pregnancy in the different groups of congenital abnormalities. The occurrence of chloramphenicol treatment in the total control group as referent was compared with the occurrence of chloramphenicol treatment in the different congenital abnormality groups during the second-third months of gestation (i.e., in the critical period for major congenital abnormalities) and a higher adjusted OR for this drug was found only in the group with undescended testis based on only two cases. At the evaluation of medically documented chloramphenicol treatment a higher OR was not found in any congenital abnormalities. Thus, chloramphenicol treatment during early pregnancy presents little, if any, teratogenic risk to the fetus in humans.

KW - Case-control analysis

KW - Chloramphenicol

KW - Congenital abnormalities

KW - Human teratogenic potential

UR - http://www.scopus.com/inward/record.url?scp=0033869733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033869733&partnerID=8YFLogxK

U2 - 10.1023/A:1007623408010

DO - 10.1023/A:1007623408010

M3 - Article

C2 - 10959939

AN - SCOPUS:0033869733

VL - 16

SP - 323

EP - 327

JO - European Journal of Epidemiology

JF - European Journal of Epidemiology

SN - 0393-2990

IS - 4

ER -